TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma

Inclusion Criteria: 1. Sign written informed consent before implementing any trial related procedures; 2. Age range from 18 to 80 years old; 3. Stage II-III and stage IV esophageal squamous cell carcinoma with only extraregional lymph node metastasis determined by histopathology; 4. Inability to undergo surgical resection or patient refusal to undergo surgery; 5. ECOG PS 0-1; 6. Expected survival time\>3 months; 7. Sufficient organ function is required for the subject to meet laboratory indicators Exclusion Criteria: 1. After esophageal or tracheal stent implantation surgery; 2. Due to the obvious invasion of tumors into adjacent organs (arteries or trachea) of the esophageal lesion, there is a higher risk of Patients at risk of bleeding or perforation, or those who have formed fistulas; 3. Diagnosed as malignant diseases other than esophageal cancer within 3 years prior to initial administration (excluding those that have undergone curative treatment) 4. Currently participating in intervention clinical research treatment, or having received other treatments within 4 weeks prior to initial administration Researching drugs or using research instruments for treatment; 5. Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs, or targeting another stimulus or synergistic inhibition of T cell receptors (such as CTLA-4, OX-40, CD137) Medications;